BIOFLOW-V: Orsiro Bests Workhorse Xience at 12 Months

04:48 EDT 31 Aug 2017 | Medscape

The biodegradable-polymer Orsiro sirolimus-eluting stent proved superior to the durable-polymer Xience everolimus-eluting stent for 12-month target lesion failure and MI in patients with up to three native de novo or restenotic coronary artery lesions.
Medscape Medical News

Original Article: BIOFLOW-V: Orsiro Bests Workhorse Xience at 12 Months


More From BioPortfolio on "BIOFLOW-V: Orsiro Bests Workhorse Xience at 12 Months"

Quick Search

Relevant Topics

Acute Coronary Syndromes ACS
Acute Coronary Syndromes (ACS) is an umbrella term for situations where the blood supplied to the heart muscle is suddenly blocked. Treatment for acute coronary syndrome includes medicines and a procedure known as angioplasty, during which doctors inflat...

A stent is a small mesh tube that's used to treat narrow or weak arteries. Arteries are blood vessels that carry blood away from your heart to other parts of your body.  A stent is placed in an artery as part of a procedure called angioplasty. &...